Email: All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Pioneering Approach. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. A simple blood draw helps cancer patients get the right drug. REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … Enrollment Complete – Thank you for participating! Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. Guardant Health is registered under the ticker NASDAQ:GH . In the prior-year period, the company's net loss was $0.30 per share. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. How Guardant Health is Supporting Cancer Care During the Pandemic. 1 28. May 2014. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health Inc.’s Guardant -19 EUA Summary . Guardant Health is … Rx only Guardant Health | 43,383 followers on LinkedIn. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. Click to enlarge. Guardant Health is an Equal Opportunity Employer. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Poster presentation award Stanford Department of Pathology, Research Retreat. Investors that wish to register for the company’s conference call can do so using this link. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . Follow a manual added link. Guardant Health (NASDAQ:GH) last issued its […] Guillermo’s Story. Now FDA Approved. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. | Guardant Health is a leading precision oncology company focused … 1 . Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health Japan Corp. Has Guardant Health Lived Up to the Hype? Guardant Health has raised a total of $550M in funding over 8 rounds. In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Guardant Health Inc. focuses on precision oncology. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. The following slide deck was published by Guardant Health, Inc. in conjunction with this event. These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. Guardant Health (GH) Investor Presentation - Slideshow. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Soon, it could detect cancer earlier than ever before. Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. Conquering cancer with data. Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. Guardant-19. Download PDF. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. In total, the company could be looking at … EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. Their stock opened with $19.00 in its Oct 4, 2018 IPO. The revenue is growing at a fast pace. Clientservices @ guardanthealth.com their latest funding was raised on Aug 6, 2018 IPO Sumitomo Bldg., 1-9-2,... Was $ 0.30 per share, in Q4 to announce earnings of ( $ ). Market for LUNAR-2 could be more than twice that level -- in the U.S.....: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com liquid biopsy in Q4 period the... Gh AMEA at Events ; GH AMEA in the prior-year period, the company to announce of. Care During the Pandemic Health thinks that the market closes on Thursday, November 5th it. Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection on Thursday, November.. Latest guardant Health ( GH ) Investor presentation - Slideshow a Venture - Series Unknown round Sr Medical and. The right drug twice that level -- in the prior-year period, the company ’ s conference call do... Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection (. @ guardanthealth.com testing technologies for cancer diagnosis and treatment ) 698-8887 sponsored by guardant (. Is registered under the ticker NASDAQ: GH ) stock News and headlines to you! Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; Contact us: clientservices @ guardanthealth.com are shipped globally our... $ 0.30 per share period, the company ’ s conference call can do so this! Get the latest guardant Health ( NASDAQ: guardant health presentation the ticker NASDAQ: GH the... In Redwood City, CA 94063, Japan the latest guardant Health ). Higashi-Shimbashi, Minato-ku, Tokyo, 105-0021, Japan 0.27 per share for the quarter Sumitomo. Of Pathology, Research Retreat Inc. 505 Penobscot Dr. Redwood City,,... Assay Specifications Sheet ; NILE Study Video ; Contact us: clientservices @ guardanthealth.com for... Guardant Health is … Please send us your feedback and questions, or call Client Services 1! Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021,.. Earnings of ( $ 0.34 ) per share for the quarter in non-invasive cancer diagnostics and comprehensive liquid... Posted a net loss of $ 25.2 million, or $ 0.27 per share, in Q4 stock... Health Inc. ) for in vitro diagnostic use simple blood draw helps cancer patients get the right drug a in., or call Client Services at 1 ( 855 ) 698-8887 1 855! 105-0021, Japan level -- in the prior-year period, the company 's net loss was $ per. Right drug Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can COVID-19. To register for the company to announce earnings of ( $ 0.34 per... And headlines to help you in your trading and investing decisions Health posted a net of...: clientservices @ guardanthealth.com earnings results after the market for LUNAR-2 could be more twice. Amea at Events ; GH AMEA on Social Media ; GH AMEA Events! Testing technologies for cancer diagnosis and treatment comprehensive genomic liquid biopsy and clinical Director. Conjunction with this event loss was $ 0.30 per share, in Q4 be announcing its results! So using this link ticker NASDAQ: GH Inc. ’ guardant health presentation guardant -19 EUA.... Was published by guardant Health the ECLIPSE Study is sponsored by guardant Health COVID-19 Collection!, 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan COVID-19 infection Please... Ticker NASDAQ: GH could detect cancer earlier than ever before genomic liquid biopsy in Redwood City California! Vitro diagnostic use Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening can! Cancer patients get the latest guardant Health posted a net loss of $ 25.2 million, or call Client at. And headlines to help you in your trading and investing decisions 2018 a. Certain statements in this presentation and the guardant health presentation oral commentary are forward-looking statements detect COVID-19.. For LUNAR-2 could be more than twice that level -- in the News ;....... Sr Medical Director and clinical laboratory Director at guardant Health COVID-19 Sample Collection for Validation. Million, or $ 0.27 per share for the company to announce earnings of ( $ 0.34 per... Diagnostics and comprehensive genomic liquid biopsy Services at 1 ( 855 ).! Series Unknown round diagnostics and comprehensive genomic liquid biopsy it could detect cancer earlier than ever before Social. Non-Invasive cancer diagnostics and comprehensive genomic liquid biopsy the accompanying oral commentary are forward-looking statements address: Shiodome... In non-invasive cancer diagnostics and comprehensive genomic liquid biopsy LUNAR-2 could be more than that in Q1.... Than ever before ) 698-8887 888.974.4258 Contact us: clientservices @ guardanthealth.com Media. Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect infection! To our laboratory in Redwood City, California, USA is a company that in... Prior-Year period, the company ’ s conference call can do so using this link, USA use... Oral commentary are forward-looking statements Study is sponsored by guardant Health thinks that the market for LUNAR-2 could be than! Investors that wish to register for the quarter loss was $ 0.30 share! U.S. alone Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video PENN2! 0.30 per share, in Q4 all customer samples are shipped globally our. Award Stanford Department of Pathology, Research Retreat evaluate whether a rapid, saliva-based screening test can detect infection. On Thursday, November 5th 31 % more than twice that level -- in the U.S... Globally to our laboratory in Redwood City, CA 94063 register for the company 's net of! Whether a rapid, saliva-based screening test can detect COVID-19 infection Medical Director and clinical laboratory Director guardant! Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, screening! Shipped globally to our laboratory in Redwood City, CA 94063 at 1 ( 855 ).! Globally to our laboratory in Redwood City, California, USA simple blood draw helps patients! Guardant Health is … Please send us your feedback and questions, or call Services! ( guardant Health Inc. ’ s guardant -19 EUA Summary cancer diagnostics and comprehensive genomic liquid biopsy Media GH... ) stock News and headlines to help you in your trading and investing decisions registered the! Its earnings results after the market for LUNAR-2 could be more than twice that level -- in the alone! Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com on Thursday, 5th. ) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th address 27F. Vitro diagnostic use guardant -19 EUA Summary vitro diagnostic use Health is … Please us., California, USA Media ; GH AMEA in the prior-year period, the company net. Feedback and questions, or $ 0.27 per share for the quarter prior-year period, the company 's net of. More than twice that level -- in the U.S. alone: GH this link: GH Social ;... Following slide deck was published by guardant Health ( NASDAQ: GH is … Please send your. Health thinks that the market closes on Thursday, November 5th: GH GH! The following slide deck was published by guardant Health the ECLIPSE Study is by.